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Abstract
Background: Benzodiazepine use is common among patients in opioid agonist therapy; this puts patients at an
increased risk of overdose and death. In this study, we examine the impact of baseline and ongoing benzodiazepine
use, and whether patients are more likely to terminate treatment with increasing proportion of benzodiazepine
positive urine samples. We also study whether benzodiazepine use differs by geographic location.
Methods: We conducted a retrospective cohort study using anonymized electronic medical records from 58 clinics
offering opioid agonist therapy in Ontario. One-year treatment retention was the primary outcome of interest and was
measured for patients who did and did not have a benzodiazepine positive urine sample in their first month of
treatment, and as a function of the proportion of benzodiazepine-positive urine samples throughout treatment. Cox
proportional hazard model was used to characterize one-year retention.
Results: Our cohort consisted of 3850 patients, with the average retention rate of 43.4%. Baseline benzodiazepine users
had a retention rate of 39.9% and non-users had a retention rate of 44%. Patients who were benzodiazepine negative
on admission benefited from an increased median days retained of 265 vs. 215 days. Patients with more than 75% of
urines positive for benzodiazepines were 175% more likely to drop out of treatment than those patients with little or
no benzodiazepine use.
Conclusions: Baseline benzodiazepine use is predictive of decreased retention. Patients who have a higher proportion
of benzodiazepine-positive urine samples are more likely to drop out of treatment compared to those who have little
or no benzodiazepine detection in their urine.
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Background
Opioids are one of the most frequently prescribed medica-
tions in Canada, and the misuse of prescription opioids is
becoming increasingly more prevalent [1]. In Ontario, the
number of opioid-related deaths increased by an alarming
242% between 1991 and 2010 [2]. This problem is particu-
larly severe in Northern Ontario, which is home to the
highest rates of both opioid prescribing and opioid-related
death within the province [3].
In a retrospective study on opioid-related deaths in
Ontario, 59.5% of deaths involved benzodiazepines
(BZD), a family of non-opioid central nervous system
depressants [1]. The short-term use of BZD is clinically
indicated in patients who suffer from anxiety, seizures,
or acute alcohol withdrawal. BZD are considered to be
high risk for dependence [4], especially when used long-
term [5]. Long-term BZD dependence can cause serious
harm, including impaired sleep, decreased mood, and a
decline in cognitive function [6].
BZD are often prescribed to patients who are receiv-
ing opioid agonist therapy (OAT) [7]. In a cross sec-
tional survey of patients in OAT, two-thirds of patients
reported concurrent BZD use [8]. Another cross-
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sectional study of 170 patients receiving OAT found
that 24% met the criteria for BZD dependence, accord-
ing to the diagnostic statistical manual of mental
disorders-IV (DSM-IV) [9]. The use of BZD during
OAT puts patients at a greater risk of overdose and
death [10]. An Alabama review of methadone fatalities
that involved other drugs found that BZD were de-
tected in 59% of deaths [11]. Additionally, patients
who are prescribed methadone and use BZD on an on-
going basis are more likely to continue polydrug use
during treatment, including cocaine and other opioids
[10]. While previous studies reveal mixed findings
about whether ongoing BZD use negatively affects
treatment retention, BZD use during treatment has
been correlated with a more complex clinical course
[10, 12, 13]. Additionally, BZD misuse is correlated
with negative patient outcomes, such as unemploy-
ment, involvement in criminal activity, and psycho-
logical distress [10].
A review of the literature reveals that most BZD pre-
scribing is in agreement with clinical guidelines; however,
there does exist some prescribing that is contrary to clin-
ical guidelines [14]. A questionnaire answered by 66 inter-
nationally recognized experts on pharmacotherapy [15]
suggested that the risks of BZD are overstated and re-
vealed support of long-term BZD use in patients suffering
from anxiety, despite the lack of evidence for effectiveness
of long-term BZD use [16]. A qualitative study of 35 gen-
eral practitioners revealed that physicians are often cau-
tious when initiating BZD use in their patients; however,
they view the prescribing of BZD as “the lesser evil” com-
pared to the patient’s psychosocial problems [17].
Along with concurrent drug use, geography is another
important factor when studying OAT retention rates. In
this study, we focus on differences in BZD use and
retention between Northern and Southern Ontario, as
well as rural and urban Ontario. An important difference
between the North and South is the population density.
Northern Ontario has approximately 10% of the popula-
tion in about 90% of the geographic area. It is for this
reason that patients often have to travel large distances
to access OAT services and pharmacies to dispense their
medication [18]. Despite facing a variety of barriers
when accessing care, patients in the North experience
higher treatment retention rates than patients in Southern
Ontario [18]. Further research must be done to better
understand why this occurs, including whether patterns of
current drug use—such as BZD use—plays a role.
While the potential risks of BZD use during OAT are
clear, it is not yet clear whether abstaining from BZD
during OAT is beneficial for patients who suffer from
co-occurring mental health disorders, where BZD may
be clinically indicated. In this study, we evaluate treat-
ment retention for patients who use BZD and those who
do not. Further, we also evaluate whether BZD use
differs by geographic location.
Methods
Cohort definition
We conducted a retrospective cohort study of patients
initiating OAT for the first time between January 1st,
2011 and June 17th, 2012 in the Province of Ontario.
We defined first time OAT as no previous history of
methadone or buprenorphine/naloxone use in the
network of clinics studied, based on review of records
dating back to 1999. Patients started on either metha-
done or Suboxone (buprenorphine/naloxone), which
were the only medications approved for opioid depend-
ence in Canada at the time of the study. Patients were
allowed to transition between these two medications
over the course of treatment. Patients were at least
15 years or older (patients <18 years of age accounted
for <1% of cohort), and were residents of Ontario. All
patients were followed from their date of OAT initiation
to the date of drug discontinuation (patient did not re-
ceive a methadone or buprenorphine dose for 30 con-
secutive days), or end of the study period (June 2013).
Data sources
The dataset used for this study was derived from
anonymized electronic medical records from a group
of 58 addiction treatment centers across the Province
of Ontario–the Ontario Addiction Treatment Centers
(OATC). Prior to data analysis, personal identifiers
were replaced with an encrypted unique identifier.
BZD use
Patients were categorized by baseline BZD use (defined
as having any BZD-positive urine samples in their first
month of treatment) and by ongoing BZD use (deter-
mined by the proportion of BZD-positive urine samples
throughout treatment). Urine toxicology screening was
performed one to two times per week on all patients
throughout their time in care via an enzyme immuno-
assay, which has the ability to detect BZD in the urine
[19]. However, this test is unable to differentiate between
different BZDs, which include (but are not limited to):
diazepam, clonazepam, and lorazepam. The majority of
urine toxicology screens reported were conducted using
an antibody reactive to diazepam (and related com-
pounds); therefore, the use of clonazepam may be
underestimated. The detection period and sensitivity
differs for each BZD, ranging from a few hours to a few
days [19].
Definition of treatment retention
Unless treatment was terminated, all patients were
followed for at least one year to a maximum follow-up
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date of June 17th, 2013. Continuous OAT was assessed on
the basis of not having a period of 30 or more consecutive
days without a dose of medication. We defined a patient
as having been retained in treatment if they completed at
least one year of continuous and uninterrupted OAT.
There is considerable evidence to suggest that one year
treatment retention is correlated with a variety of positive
health outcomes, including reduced drug use, relapse,
hospitalization, and illegal activity [20, 21]. In the event
that a patient transitioned to a non-OATC clinic, was in-
carcerated, hospitalized, or was otherwise prevented from
refilling their prescription, it is possible for type 1 error to
occur.
Statistical analysis
Descriptive statistics were summarized for baseline char-
acteristics of patients, and standardized differences were
used to compare patients in the various BZD use groups
(Table 1). Baseline characteristics included: percentage
of patients that were male/female, Northern/Southern,
and rural/urban, median age, median peak methadone
dose, median days retained, the percentage of BZD-
positive urine samples, and the one-year retention rate.
For the purpose of this study, only a patient’s first
treatment episode was considered. For the primary
analysis (risk of treatment drop out), a Cox propor-
tional hazard analysis was used to characterize the
time to treatment discontinuation (Fig. 1). The rela-
tive likelihood of treatment termination between the
BZD positive and negative patient groups was calcu-
lated from hazard ratios, adjusting for the impact of
age, gender, Northern and rural location. Cox propor-
tional hazard analysis and log-rank test were per-
formed using SPSS 24.
Results
Patient demographics
Our cohort consisted of 3850 patients, with a median
age of 31.4 years old and 60% of patients being male.
36% of patients resided in Northern Ontario and 16%
lived in a rural setting. The Cox proportional hazard
model found that those patients living in the North were
40.7% less likely to drop out of treatment by the one-
year mark compared to patients in the South. Male pa-
tients were 30.2% more likely to drop out of treatment
than female patients. There were no significant differ-
ences in treatment retention for patients living in rural
or urban centres.
Table 1 Characteristics of baseline BZD users and non-users
Initially negative (n = 3288, 85.4%) Initially positive (n = 562, 14.6%)
Male/female 1975 (60.1%)/1313 (39.9%) 316 (56.2%)/246 (43.8%)
North/South 1239 (37.7%)/2048 (62.3%) 166 (29.5%)/396 (70.5%)
Urban/rural 2753 (83.8%)/543 (16.2%) 499 (88.8%)/63 (11.2%)
Median age (Q1, Q3; SD) 30.8 (25.3, 39.4; SD = 10.2) 34.3 (28.1, 45.3; SD = 10.9)
Median peak methadone dose (Q1, Q3; SD) 75 (50, 100; SD = 33) 85 (55, 115; SD = 36)
Median peak suboxone dose ( Q1, Q3; SD) 8 (8, 16; SD = 7) 12 (8, 20; SD = 8)
Median days retained (Q1, Q3; SD) 265 (56, 526; SD = 272) 215 (53, 519; SD = 270)
Median percent positive results (Q1, Q3; SD) 0.0 (0.0, 0.0; SD = 4.9) 21.4 (6.8, 55.1; SD = 32.1)
Percent positive results [0, 25) 3252 (98.9%) 302 (53.7%)
[25, 50) 31 (0.9%) 96 (17.1%)
[50, 75) 4 (0.1%) 68 (12.1%)
[75, 100] 1 (<0.1%) 96 (17.1%)
At month 3
Day 60 to 90
Positive/negative 144 (6.0%)/2276 (94.0%) 204 (50.5%)/200 (49.5%)
Retained 2420 (73.6%) 404 (71.9%)
At Month 6
Day 150 to 180
Positive/negative 109 (5.6%)/1850 (94.4%) 128 (40.9%)/185 (59.1%)
Retained 1959 (59.6%) 313 (55.7%)
At Month 9
Day 240 to 270
Positive/negative 88 (5.2%)/1601 (94.8%) 104 (39.0%)/163 (61.0%)
Retained 1689 (51.4%) 267 (47.5%)
At Month 12
Day 330 to 360
Positive/negative 80 (5.3%)/1443 (94.7%) 74 (31.2%)/163 (68.8%)
Retained 1523 (46.3%) 237 (42.2%)
Retained/not retained 365 Days 1447 (44.0%)/1841 (56.0%) 224 (39.9%)/338 (60.1%)
Descriptive statistics were summarized for baseline characteristics of patients, and standardized differences were used to compare patient groups. Patients were
considered baseline BZD users if they had any BZD positive urine samples in the first month of treatment
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Baseline BZD use
Patients were stratified by baseline BZD use, which was
defined by the presence of any BZD-positive urine sam-
ples in the first month of treatment. Of the 3850 pa-
tients, 562 (15%) were considered baseline BZD users
and 3288 (85%) non-users. The ratio of female to male
patients was greater in the BZD use group with 43.8% of
BZD users being female, compared to only 39.9% of
non-users being female. Female patients were 34.5%
more likely to be baseline BZD users than were males,
according to the Cox proportional hazard model. An-
other difference in the two groups was in age, with the
positive group having a greater median age of 34.3 years
compared to 30.8 years. Hazard ratios found that pa-
tients were 25.5% less likely to have a BZD-positive urine
sample in their first month of treatment if they lived in a
rural area and were 23.6% less likely to have a BZD-
positive urine sample in their first month of treatment if
they lived in the North. Compared to patients who were
considered non-baseline users, baseline BZD users had
an increased median peak dose of methadone (85 vs.
75 mg) and had a lower median retention of 215 days,
compared to 265 days.
Retention and baseline BZD use
The following variables were included in the Cox propor-
tional hazard model: age [aHR = 0.98 (95% CI 0.975–
0.984)], gender (female [aHR = 0.768 (95% CI 0.70–0.84)]),
geography (North [aHR = 0.59 (95% CI 0.538–0.655)] and
rural [aHR = 0.982 (95% CI 0.863–1.118)], and first-month
BZD use [aHR = 1.149 (95% CI 1.022–1.292)]. For those
patients considered baseline BZD users, the one-year re-
tention rate was 39.9%. For those patients who were BZD
negative on admission, the one-year retention rate was
44%. Of the first month BZD users that remained at
one year, 31.2% were BZD positive. Of the 562 patients
who were BZD positive in their first month of treatment,
49% of those that were retained were negative at 3 months,
59% at 6 months, 61% at 9 months, and 69% at the one-
year mark. Of the baseline non-users who remained at the
one-year mark, 95% were BZD negative. Importantly, pa-
tients were 14.9% more likely to drop out of treatment if
they had BZD-positive urine samples in their first month
of treatment.
Proportion of BZD-positive urine samples
In addition to being categorized by first-month BZD use,
patients were also stratified by the proportion of BZD-
positive urine samples throughout treatment: 0–25,
25–50, 50–75, and 75–100%. Of the 3850 patients,
3556 had BZD-positive urine samples less than 25%
of the time. These patients experienced a one-year re-
tention rate of 45%. 127 patients had BZD-positive
urine samples 25–50% of the time, with a retention
rate of 32%. These patients were 26.6% more likely to
not be retained, compared to those patients in the
<25% group. 72 patients had BZD-positive urine sam-
ples between 50–75% of the time, and they experi-
enced a retention rate of 33%. These patients were
37.4% more likely to terminate treatment prematurely
Fig. 1 Treatment retention by baseline BZD use. A Cox proportional hazard analysis was used to characterize the time to treatment
discontinuation between the patient groups. Log-rank comparison of these curves yielded a chi-square value of 2.883 with a non-significant
p value of 0.0895. Baseline BZD users were 14.9% more likely to drop out of treatment than baseline non-users [aHR = 1.15(95% CI 1.02–1.29)]
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than the <25% group. Lastly, 97 patients had BZD-
positive urine samples more than 75% of the time,
and they suffered the lowest retention rate of 14%.
These patients were a substantial 174.4% more likely
to not be retained in treatment, compared to the
<25% group (Fig. 2).
BZD use and geography
Patients were categorized as residing in Northern On-
tario or Southern Ontario according to the Local Health
Integration Network (LHIN) in which they lived;
patients residing in LHIN 13 or 14 were considered
Northern residents. For the proportion of BZD-positive
urine samples, patients in the North had retention rates
of 56, 33, 17, and 13%. Patients in the South experienced
retention rates of 38, 32, 36, and 14%. In the Northern
population, the greater the proportion of BZD-positive
urine samples, the lower the retention; however, in the
Southern population, the decrease was less pronounced
(Fig. 3). Instead, it appears that only patients with >75%
of urines BZD positive suffer the lowest retention rates.
Discussion
Previous studies have revealed mixed findings about
whether BZD use impacts OAT retention. A review of
BZD use in OAT suggests that most studies have found
that baseline BZD use is not predictive of decreased
retention [6]; however, this is contrary to our findings.
Our findings support the idea that baseline BZD use is
predictive of treatment drop out, with these patients
being 14.9% more likely to terminate treatment prema-
turely. Additionally, our results indicate that with
increasing proportion of BZD-positive urine samples,
patients are at increased risk of premature drop out;
therefore, both BZD use at treatment outset and inten-
sity of BZD use during OAT are correlated with de-
creased retention. Patients taking BZD may be more
likely to drop out of treatment given that BZD use is
associated with polydrug use, risk-taking behaviors, un-
employment [22, 23], involvement in criminal activity
[23], and psychological distress [10]. These additional
complexities may hinder patients’ ability to thrive in
treatment and make them more likely to terminate treat-
ment prematurely. Additionally, patients using BZD
while receiving OAT are at increased risk of overdose
and death [1, 24], an event that would be captured as
premature drop out in our analysis.
Compared to previous studies on patients in OAT, the
median age of our patient sample was younger, at
31 years (median age = 34.6 [10]; median age = 35 [9];
median age = 47 [25]); however, the age distribution in
our dataset seems to reflect the opioid dependent popu-
lation in Ontario at the time of the study. This is sup-
ported by a cross-sectional study of all opioid-related
Fig. 2 Treatment retention by proportion of BZD-positive urine samples. A Cox proportional hazard analysis was used to characterize the time to
treatment discontinuation across the four patient groups. Patients with 25–50% of urines BZD-positive were 26.6% more likely to drop out of
treatment than patients in the 0–25% reference group [aHR = 1.26 (95% CI 1.02–1.57)]. Patients with 50–75% of urines BZD-positive were 37.4%
more likely to drop out of treatment than patients in the 0–25% reference group [aHR = 1.37(95% CI 1.03–1.832)]. Patients with 75–100% of urines
BZD positive were 174.4% more likely to drop out of treatment than patients in the 0–25% reference group [aHR = 2.74(95% CI 2.19–3.43)]
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deaths in Ontario between 1991 and 2010, which found
that most opioid-related deaths occurred among young
adults aged 25–34 [2]. A study relying on self-reports of
high school students found that opioid use is increasing
among adolescence [26]; therefore, it is possible that the
opioid-dependent population in Ontario has gotten
younger in recent years, compared to the times and lo-
cations at which the other studies on BZD use were
conducted.
In terms of concurrent drug use, 15% of our patient
population was BZD-positive in their first month of
treatment. Compared to previous studies, this number is
low [6]. A review by Lintzeris et al. found that problem-
atic BZD use amongst patients receiving OAT varies
from 18 to 50% [6]; however, it is important to consider
that many of these studies are international, as drug
consumption and treatment differ throughout the world.
At the time of this study, methadone and buprenor-
phine/naloxone were the only two approved medications
for OAT in Canada; however, in other parts of the world,
other forms of OAT—including heroin assisted therapy,
slow-release morphine, and intramuscular slow-release
naltrexone—exist, which have been shown to be effective
in the treatment of opioid dependence [27, 28]. Regard-
ing BZD use among patients in OAT, studies have found
that BZD use is common not only in Canada, but also in
countries across Europe, North America, and in
Australia [8, 29–31].
Our findings indicate that BZD use is more prevalent
in the female population, which is supported by previous
studies [10]. The higher prevalence of BZD use in this
population may be explained by the fact that females in
OAT suffer from more psychiatric comorbidity than
their male counterparts [32, 33]. Studies have also found
that female patients are more likely to receive a BZD
prescription than males, [29] and that the risks associ-
ated with prescribed BZD (e.g., hospital visits, accidental
injury) are increased in the female population [34].
Given that previous studies have found that females are
more likely to use BZD, more likely to be prescribed
BZD, and more likely to suffer from psychological co-
morbidities, it would seem reasonable that females are
also more likely to self-medicate with non-prescribed
BZD as well.
We also found a difference in the age of baseline users
and non-users, with baseline users having a median age
of 34.3 years and non-users having a median age of
30.8 years. It may be the case that patients who have
more severe mental health disorders (and use BZD to
self-medicate) take longer to present to treatment.
Our results suggest that geography is an important
factor to consider when studying BZD use. We found
that patients living in rural areas, and those patients liv-
ing in the North, were less likely to be baseline BZD
users. When studying the impact of geography on reten-
tion, we confirmed the earlier finding that patients in
the North were more likely to be retained in treatment;
however, we failed to confirm the correlation between
rurality and retention in this smaller sample size [18].
The higher rates of retention in the North may seem
surprising, given that these patients face a variety of bar-
riers when accessing health care. In remote Northern
communities, patients often have to travel long distances
to access OAT-prescribing physicians and the pharmacy
that dispenses their methadone or buprenorphine [18].
It seems somewhat intuitive that given the added diffi-
culties, these patients would experience decreased reten-




0-25% 25-50% 50-75% 75-100% 0-25% 25-50% 50-75% 75-100%
Fig. 3 Proportion of patients retained in treatment for one year, by frequency of BZD use, comparing North vs. South. The pattern of decreased
retention with increased proportion of BZD-positive urine samples is not seen in the Southern population, as it is in the Northern population.
However, Southern patients with a high proportion of BZD-positive urine samples (≥75%) experienced decreased retention rates
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North were 41% less likely to terminate treatment pre-
maturely than were Southern patients. Given that
Northern patients are less likely to be BZD users and
BZD use is predictive of drop out, the higher rates of re-
tention may be partially explained by less BZD use in
the North. However, given that the Northern population
was more likely to use cocaine and that cocaine use is
predictive of treatment drop out [20], there are likely
other reasons why this population benefits from greater
retention. Northern patients who overcome the barriers
to treatment entry may be more motivated to be suc-
cessful in their treatment. The decreased BZD use in
Northern and rural patients may be explained by in-
accessibility in terms of availability or cost of non-
prescribed BZD. Although we were unable to quantify
illicit BZD use, we would expect that illicit BZD would
be less accessible in Northern Ontario than other drugs,
including cocaine and non-prescribed opioids.
Of the 3288 patients who were considered baseline
non-users, the vast majority (~95%) of patients who
were retained were also BZD negative at the one-year
mark. For the remaining 5%, it may be the case that pa-
tients received a BZD prescription during the course of
their treatment. Of the 562 patients who were BZD-
positive in their first month of treatment, the proportion
that continued to have BZD-positive samples declined
over time retained in treatment. Given that OAT does
not treat BZD dependence, it may seem surprising that
the majority of BZD users terminate BZD use during
treatment; however, it may be the case that many of the
initially positive patients were heavy BZD users and
dropped out of treatment before reaching the 3rd, 9th,
or 12th month. It may also be the result of contingency
management, whereby a patient is motivated to abstain
from concurrent drug use in order to obtain carried (i.e.,
take home) doses. Contingency management might en-
courage a patient to decrease BZD use, given that it has
been shown to reduce the use of other drugs in patients
who are receiving OAT [21].
Although our patient sample had fewer BZD users
than expected, it is important to consider why BZD use
is so prevalent in OAT. One theory is that there is an in-
creased prevalence of comorbid mental health issue-
s—including depression, anxiety, and insomnia—among
patients enrolled in OAT [35, 36]. It is for this reason
that patients are often prescribed BZD to treat their con-
current mental health disorders [37]. A retrospective co-
hort study of over 2000 patients receiving OAT found
that 40% of patients had received at least one BZD pre-
scription [29]. The current guidelines on how to manage
patients with opioid dependence and co-occurring men-
tal health disorders—for which BZD are clinically indica-
ted—are unclear [38]. Further research needs to inform
physicians as to how they should manage these complex
patients. However, it is important to note that not all
BZD use is prescribed. A retrospective study of patients
receiving methadone found that nearly 35% of patients
who were BZD-positive did not have an associated pre-
scription [39].
One of the main limitations of this study is the inabil-
ity to detect whether a patient received a BZD prescrip-
tion from a physician other than their OAT provider.
The number of patients that received a BZD prescription
from their OAT provider was known; however, this
number was less than 7.2%. This number is likely this
low due to the majority of BZD prescriptions coming
from physicians outside the OATC network. A retro-
spective cohort study that utilized a prescription data-
base found that over 60% of BZD prescriptions were
written by a physician other than the patient’s OAT pro-
vider [29]; therefore, it is very likely that our detection of
BZD prescriptions is insufficient. While this study cap-
tures the impact of general BZD use on OAT retention,
it does not necessarily differentiate between clinical BZD
use for mental health disorders and non-prescribed use.
It is possible that a large proportion of our patient sam-
ple did have BZD prescriptions and were using BZD as
clinically prescribed from a non-OATC physician. An-
other limitation is that we were unable to determine the
dose of BZD taken by patients. Lastly, if a patient
dropped out of treatment, we were not able to deter-
mine whether the patient simply terminated all OAT,
began treatment at a non-OATC clinic, was incarcer-
ated, hospitalized, or died.
This study also has several strengths. While BZD use
in OAT has been studied previously, it has not been
studied in a regional context—in this case Northern vs.
Southern Ontario. Of the studies that have been done,
few have been longitudinal. Those studies that were lon-
gitudinal either had a much smaller sample size, relied
on self-reported data, or did not use a survival analysis
to quantify the impact of BZD use and geography on
treatment retention. Other strengths regarding study de-
sign include the large sample size, the method of data
collection, and the patient population. With nearly 4000
patients in our cohort, this study captures a substantial
proportion of all patients receiving OAT in Ontario.
Additionally, this study did not rely on patient self-
report, as did many of the previous studies. Lastly, the
fact that all patients in the cohort were from one net-
work of clinics adds strength to the comparisons made
between patients.
Conclusions
The findings of this study suggest that BZD use is a
marker for a greater clinical complexity, and puts pa-
tients at increased risk of premature OAT discontinu-
ation. Given that treatment retention is correlated with
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better patient outcomes [40, 41], it is important that
physicians be cognizant of BZD detection in patients’
urine samples, as this could be a marker for decreased
retention. Additionally, physicians should exercise cau-
tion when prescribing BZD to patients who are receiving
OAT; however, further research needs to be done to bet-
ter understand how prescribed BZD use and non-
prescribed use differentially impact treatment retention.
Employing mixed methodologies to understand factors
such as reason for BZD use or reason for treatment ter-
mination would also add strength to this study.
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